Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

TR1 Notification

2 Jun 2023 16:48

RNS Number : 5535B
Ergomed plc
02 June 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN7ZCY67

Issuer Name

ERGOMED PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Octopus Investments Limited

City of registered office (if applicable)

London

Country of registered office (if applicable)

England

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

01-Jun-2023

6. Date on which Issuer notified

02-Jun-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

12.030000

0.000000

12.030000

6110199

Position of previous notification (if applicable)

11.530000

0.000000

11.530000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BN7ZCY67

6110199

12.030000

Sub Total 8.A

6110199

12.030000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Octopus Capital Limited

Octopus Investments Limited

12.030000

12.030000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

02-Jun-2023

13. Place Of Completion

33 Holborn, London, EC1N 2HT

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDZGGVKZVGFZM
Date   Source Headline
16th Nov 20167:00 amRNSResearch Update from Modus Therapeutics
15th Nov 20164:33 pmRNSHolding(s) in Company
1st Nov 20167:00 amRNSCo-Development Agreement with Asarina AB
24th Oct 20167:00 amRNSErgomed notes news from co-development partner
14th Oct 20167:00 amRNSFourth licensing agreement for Zoptrex
26th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSContract win validates rationale of acquisitions
16th Sep 201610:56 amRNSErgomed receives a "buy" recommendation
8th Sep 20167:00 amRNSRecruitment completed in phase IIa clinical trial
7th Sep 201611:30 amRNSNotice of Results
2nd Sep 20167:00 amRNSCo-development partner announces licensing deals
15th Aug 20167:01 amRNSChange of Nominated Adviser
15th Aug 20167:00 amRNSDisclosure of Directors' Appointments
27th Jun 20161:55 pmRNSResult of AGM
27th Jun 20167:00 amRNSUS expansion and opening of office in Boston
20th Jun 20165:49 pmRNSNotice of AGM
14th Jun 201611:49 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAcquisition
6th Jun 20163:31 pmRNSHolding(s) in Company
31st May 20164:45 pmRNSTotal Voting Rights
25th May 201611:55 amRNSHolding(s) in Company
23rd May 201611:10 amRNSResult of Meeting
16th May 20167:00 amRNSPlacing Update
4th May 201612:30 pmRNSProposed acquisition of Haemostatix Limited
30th Mar 201612:00 pmRNSNotice of Results
1st Feb 20161:42 pmRNSHolding(s) in Company
1st Feb 20167:00 amRNSTrading Statement
11th Jan 20167:02 amRNSErgomed Award of Share Options to Director
11th Jan 20167:00 amRNSErgomed announces Board changes
24th Dec 20157:00 amRNSErgomed Awards Share Options
17th Dec 20157:00 amRNSHolding(s) in Company
16th Dec 20157:00 amRNSErgomed Update on Co-Development Partnerships
5th Nov 20157:00 amRNSHolding(s) in Company
29th Oct 201510:00 amRNSErgomed plc to present at German Equity Forum 2015
21st Oct 20159:21 amRNSErgomed Co-Development Partner News
14th Oct 20157:00 amRNSErgomed's Co-Development Partner News
13th Oct 20157:00 amRNSErgomed and Dilaforette Initiate Phase II
5th Oct 20151:09 pmRNSErgomed expands co-development with CEL-SCI
29th Sep 20157:01 amRNSErgomed Interim Results 2015
23rd Sep 20158:00 amRNSErgomed shortlisted for Leading Industry Award
15th Sep 20157:00 amRNSNotice of Results
14th Aug 20157:00 amRNSCo-development partner news
21st Jul 20152:30 pmRNSHolding(s) in Company
20th Jul 20154:20 pmRNSSecondary Placing Of Ordinary Shares in Ergomed
14th Jul 20159:56 amRNSCo-development partner news
10th Jul 20157:00 amRNSAppointment of Director - additional information
2nd Jul 20157:00 amRNSErgomed Strengthens Management Team & Board
30th Jun 201512:43 pmRNSCo-development partner news
25th Jun 20151:06 pmRNSCo-development partner news
19th Jun 201512:35 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.